Published in Medical Letter on the CDC and FDA, April 18th, 2004
The company reported a net loss of $12,875,434, or $0.68 per basic and diluted share, for the fourth quarter of 2003, compared to a net loss of $11,404,137, or $0.61 per basic and diluted share in the fourth quarter of 2002.
The company reported no revenue for the fourth quarters ended December 31, 2003 and 2002.
The increase in the fourth-quarter 2003 net loss is a direct result of an increase in research and development expenses of $1,865,436, primarily for the development of IL13-PE38QQR, the company's lead product...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.